Placebo for pembrolizumab

DRUG10 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Carcinoma, Ovarian EpithelialEndometrial NeoplasmsEndometrial cancerFallopian Tube CancerFallopian Tube NeoplasmsGastric and gastric esophageal junction (GEJ) adenocarcinomaGastric or gastroesophageal junction (GEJ) adenocarcinomaMetastatic hormone sensitive prostate cancer

Phase 3

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

CompletedNCT03675737

Merck Sharp & Dohme LLCStomach Neoplasms

Start: 2018-11-08End: 2025-03-03Updated: 2026-02-27

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Active, not recruitingNCT03740165

Merck Sharp & Dohme LLCFallopian Tube Cancer, Ovarian Cancer, Peritoneal Neoplasms

Start: 2018-12-18End: 2026-05-29Updated: 2025-10-22

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

CompletedNCT04221945

Merck Sharp & Dohme LLCUterine Cervical Neoplasms

Start: 2020-05-12End: 2026-01-26Updated: 2026-02-20

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Active, not recruitingNCT04634877

Merck Sharp & Dohme LLCEndometrial Neoplasms

Start: 2021-01-10End: 2026-09-15Target: 990Updated: 2025-06-09

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

WithdrawnNCT04859582

Merck Sharp & Dohme LLCStomach Neoplasms

Start: 2018-11-08End: 2024-11-29Updated: 2021-12-16

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

Active, not recruitingNCT05116189

Merck Sharp & Dohme LLCCarcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Cancer

Start: 2021-12-13End: 2027-07-16Updated: 2026-03-09

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Active, not recruitingCTIS2022-501973-37-00

Merck Sharp & Dohme LLCEndometrial cancer

Start: 2020-01-30Target: 300Updated: 2026-01-27

A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)

CompletedCTIS2023-508253-98-00

Merck Sharp & Dohme LLCGastric or gastroesophageal junction (GEJ) adenocarcinoma

Start: 2018-10-05End: 2025-11-11Target: 167Updated: 2025-09-12

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

CompletedCTIS2023-507024-24-00

Merck Sharp & Dohme LLCMetastatic hormone sensitive prostate cancer

Start: 2020-05-05End: 2026-01-22Target: 122Updated: 2026-01-26

A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859)

CompletedCTIS2023-508890-10-00

Merck Sharp & Dohme LLCGastric and gastric esophageal junction (GEJ) adenocarcinoma

Start: 2018-12-05End: 2025-03-03Target: 268Updated: 2025-03-19

Related Papers

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.

2025-10-01

First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study.

2025-08-01

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.

2025-06-301 citations

Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

Journal of Clinical Oncology2025-06-043 citations

KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Journal of Clinical Oncology2025-05-281 citations

First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.

2025-03-012 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.

Journal of Clinical Oncology2025-01-271 citations

Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.

Journal of Clinical Oncology2025-01-27

Q-TWiST analysis of pembrolizumab or placebo plus chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer in KEYNOTE-859.

Journal of Clinical Oncology2025-01-27

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors

Journal of Clinical Oncology2024-10-1618 citations

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

2024-09-1484 citations

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.

2024-09-1445 citations

Pharmacotherapy for cervical cancer: current standard of care and new perspectives.

2024-08-271 citations

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

British Journal of Cancer2024-07-0617 citations

Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Gastric Cancer2024-07-0252 citations

Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study.

Journal of Clinical Oncology2024-06-017 citations

23O A randomized, phase III, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for patients enrolled in Asia

ESMO Open2024-06-012 citations

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

2024-03-20228 citations

161 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study

2024-03-013 citations

285 Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer

2024-03-011 citations

23 more papers not shown